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Background: Non-typhoid Salmonella (NTS) is a leading cause of food-borne illness with more than 90
million annual cases and an emerging antimicrobial resistance among the strains worldwide. Paradoxi-
cally, no vaccines are available against these pathogens. Numerous NTS strains share surface O-antigens
with Salmonella enterica serotype Typhi. As intestinal antibodies against O-antigens have proven protec-
tive against NTS in animal experiments, it appears conceivable that the oral whole-cell typhoid vaccine,
Salmonella Typhi Ty21a (Vivotif®), which effectively elicits intestinal antibodies against O-antigens, could
exhibit cross-protective efﬁcacy against NTS. We sought immunological evidence in support of cross-
protective efﬁcacy of Ty21a against NTS.
Materials and methods: 35 volunteers receiving Ty21a vaccine and ﬁve patients with enteric fever were
investigated with ELISPOT for circulating plasmablasts secreting antibodies reactive with Salmonella
Typhi and six different NTS serotypes. These plasmablasts were also analysed for homing receptor
expressions.
Results: In all vaccinees and patients, a strong gut-directed cross-reactive plasmablast response was
found against serotypes sharing the two O-antigens with Salmonella Typhi (O-9,12) (in vaccinees, mean:
95%CI 268: 228–508 and 363: 234–493 plasmablasts/106PBMC against Salmonella Typhi and Enteritidis).
Responses against strains sharing one O-antigen (O-12) were weaker (222: 105–338 against Salmonella
Typhimurium),while no signiﬁcant reactivitywas detected against strainswithout typhoidal O-antigens.
Conclusions: Intestinal antibodies against O-antigens protect against NTS in animal experiments. Ty21a
was found to elicit intestinal immune responses cross-reactive with NTS strains sharing O-antigens with
Ty21a. These include the most common NTS, Salmonella Enteritidis and Typhimurium. The data suggest
s-prothat Ty21a may have cros
. IntroductionNon-typhoid Salmonella (NTS) is a leading cause of food-
orne illness both in developing and developed countries, with an
Abbreviations: ALS, antibodies in lymphocyte supernatants; ASC, antibody-
ecreting cell; CLA, cutaneous lymphocyte antigen; HR, homing receptor; iNTS,
nvasive non-typhoid Salmonella; NTS, non-typhoid Salmonella; PBMC, peripheral
lood mononuclear cell; PBS, phosphate buffered saline.
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estimate of more than 90 million cases of gastroenteritis and
155,000 deaths occurring globally each year [1]. Clinical mani-
festations of non-typhoidal salmonellosis include gastroenteritis
and bacteremia as well as endovascular and local infections [2].
By far the most common manifestation is gastroenteritis, invasive
NTS (iNTS) occuring in up to 5% of immunocompetent individ-
uals [3]. In Sub-Saharan Africa the incidence of iNTS appears to
be much higher than elsewhere, particularly among children and
HIV-infected adults [2–6]. Gastroenteritis is usually self-limited
and does not require antibiotics, although in iNTS appropriate
antimicrobial therapy can be lifesaving. However, the increasing
antimicrobial resistance and emergence of multiresistant strains
among NTS pose a serious problem for public health [7,8] and
veterinarymedicineworldwide [2,9]. This focuses attentiononvac-
cines, yet, there are currently no vaccines against NTS available for
clinical use.
cine 3
t
t
s
(
p
u
s
c
t
s
m
a
s
l
1
n
e
a
a
p
c
i
g
a
a
m
t
D
o
i
h
c
m
a
p
t
r
2
2
f
S
i
a
v
b
e
a
v
t
M
R
W
2
a
oA. Kantele et al. / Vac
The current nomenclature divides the genus Salmonella into
wo species, Salmonella enterica and Salmonella bongori [10,11],
he former being further divided into six subspecies. The sub-
pecies enterica comprises human-restricted typhoidal serotypes
Typhi and Paratyphi) causing enteric fever (typhoid and paraty-
hoid fever), and NTS serotypes causing mostly gastroenteritis,
sually of zoonotic origin [10,11]. There are more than 2400 NTS
erotypes, some of which are closely related both phenotypi-
ally and genetically [10]. Interestingly, both Salmonella Typhi and
he most common NTS, Salmonella Enteritidis [10–12], share the
ame O-antigen proﬁle O-9,12, and even the second most com-
on serotype, Salmonella Typhimurium [10,11], shares the O-12
ntigen with Salmonella Typhi. This opens up an interesting pos-
ibility, as one of the currently available typhoid vaccines, the oral
ivewhole cell vaccine SalmonellaTyphi Ty21a, carries bothO-9 and
2 antigens, and has been well documented to induce an intesti-
al IgA response reactive with these structures [13–16]. It is well
stablished in animal experiments that intestinal or mucosal SIgA
ntibodies against O-antigen confer protection [17–23]. Thus, it
ppears that this vaccine could have potential for providing cross-
rotection against numerous NTS strains, including the two most
ommon types.
Intestinal antibody responses can be studied either by exam-
ning secretory IgA in the intestinal secretions or by examining
ut-derived plasmablasts from the peripheral blood. The latter
pproach is based on the recirculation of intestinal lymphocytes
fter antigen encounter: activated antigen-speciﬁc plasmablasts
igrate to mesenteric lymph nodes from where they return via
he lymphatics and blood to the intestinal lamina propria [24,25].
etected in the peripheral blood while migrating, approximately
neweek after antigen encounter, these cells can be used for study-
ng intestinal immune responses [14–16,26,27]. Numerous studies
ave characterized Salmonella Typhi-speciﬁc plasmablasts in the
irculation after oral Ty21a vaccination [14–16]. All of these plas-
ablasts carry the intestinal homing receptor,47 [16,26], which
cts as an indicator for their migration to the intestinal lamina pro-
ria [24,25]. InNTSdisease the intestinal immune response appears
o be of central importance. The present study explores the cross-
eactive potential of Ty21a against NTS strains.
. Materials and methods
.1. Study design
Volunteers vaccinated with Ty21a and patients with enteric
ever were examined for circulating plasmablasts speciﬁc for
almonella Typhi and six different NTS strains. These cells were
dentiﬁed by enzyme-linked immunosorbent spot assay (ELISPOT)
s antigen-speciﬁc antibody-secreting cells (ASC). In a subgroup of
accinees, the homing potentials of these cells were characterized
y combining immunomagnetic cell sorting with the ELISPOT. Lev-
ls of speciﬁc antibodies were determined by ELISA in the serum
nd ALS (antibodies in lymphocyte supernatants) samples of the
accinees.
The study protocol was approved by the ethics commit-
ee of the Helsinki University Central Hospital and the Finnish
edicines Agency and registered in the International Standard
andomised Controlled Trial Number Register (ISRCTN68125331).
ritten informed consent was obtained from all study subjects.
.2. Volunteers, vaccinations and samplesThirty-ﬁvehealthyFinnish-bornvolunteers (21 female, 14male;
ged 18–62, mean 32 years) with no history of enteric fever
r typhoid vaccination, were given the oral vaccine containing0 (2012) 7238–7245 7239
≥2×109 live Salmonella Typhi Ty21a bacteria (Vivotif® Crucell NV,
Leiden, The Netherlands, lot 3001777), administered one capsule
on each of days 0, 2, and 4 as recommended by the manufac-
turer. The vaccine provedwell-tolerated: only 2 out of 35 vaccinees
reported stomachache and 1/35 felt nauseated.
The typhoid fever patients (three females, onemale; aged 22–30
years) included twoFinnish-born travellers returning fromCentral-
America and India, a Sri Lankan applying for asylum in Finland,
and a Nepalese immigrant with an infection relapse one month
after the ﬁrst episode. The patient with paratyphoid fever caused
by Salmonella Paratyphi A (sharing O-12 antigen with S. Typhi) was
a 30-year-old female immigrant from India. All these patients were
treated at the Division of Infectious Diseases, Helsinki University
Hospital. Typhoid and paratyphoid fever were diagnosed by blood
culture.
In our previous studies on mucosal [14–16] and parenteral
[16,28] immunization, ASC have been found to appear transiently
in the circulation on day 2–3, peaking on day 7 [14,15]. On the basis
of these kinetics, blood sampleswere drawnbefore and 7 days after
vaccination (ELISPOT andALS) or 7–10 days after the onset of infec-
tion symptoms (ELISPOT). Serum samples were collected before
and 28 days after vaccination.
2.3. Antigens
Eight bacterial strains altogether were used as antigens in the
ELISPOT assay (Table 1). Four Salmonella strains shared at least one
O-antigenic determinant (9, 12 or both) with Salmonella Typhi, and
two harbored different O-antigens (O-6,7 or 6,8). Yersinia enteroco-
litica was used as a negative control. Bacteria were formalin-killed,
as described earlier [15], and the concentration of the suspension
was adjusted to 109 bacteria/mL in PBS (phosphate buffered saline).
2.4. Isolation of peripheral blood mononuclear cells (PBMC)
PBMC were separated using Ficoll-paque density gradient cen-
trifugation as described previously [15].
2.5. Separation of the receptor-negative and -positive cell
populations
The expressions of HR on Salmonella Typhi and Enteritidis
-speciﬁc ASC were explored in 15 vaccinees. Separation of
the cells into HR-positive and -negative populations has been
described earlier [16,26–28]. Brieﬂy, aliquots of cell suspensions
(3.4×106 PBMC were investigated per HR) were incubated with
monoclonal antibodies against 47 (ACT-1, Millennium Pharma-
ceuticals, Cambridge, MA), L-selectin (Leu 8, Becton Dickinson,
Erenbodegem-Aalst, Belgium), or CLA (HECA-452, a gift from Dr.
Sirpa Jalkanen, Finland).Next, the cellswere incubatedwithDynal®
M-450 magnetic beads coated with sheep anti-mouse IgG (Dyn-
abeads, Dynal Biotech, Oslo), followed by magnetic separation.
Separated cells were immediately studied with the ELISPOT assay.
2.6. ELISPOT assay
The isolated PBMC and, for HR analyses, the receptor-positive
and -negative cell populations were assayed for antigen-speciﬁc
ASC using ELISPOT, as described earlier [15]. Brieﬂy, 96-well
microtiter plates (Maxisorp, Nunc, Roskilde, Denmark)were coated
with a whole cell preparation of formalin-killed bacteria. The
cells were incubated in the wells for 2h (2×106 PBMC/mL,
50L/well, total 2.4×106 PBMC per antigen), and antibodies
secretedwere detectedwith alkaline phosphatase-conjugated goat
anti-human IgA (Sigma–Aldrich), IgG (Sigma–Aldrich) and IgM
7240 A. Kantele et al. / Vaccine 3
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(SouthernBiotech, Birmingham, England). The substrate (5-bromo-
4-chloro-3-indolyl phosphate p-toluidine salt; Sigma–Aldrich)was
added in melted agarose. The spots were enumerated with an AID
Elispot reader, each spot interpretedasaprintof oneASC. The speci-
ﬁcity, linearity, stability, and intermediate precision of the ELISPOT
assay were validated. A response was deﬁned as at least 3 ASC/106
PBMC and marked as LOD (limit of detection) in the Figures. This
limit has been determined over the assay validation process.
2.7. ALS cultures
PBMC were cultured in RPMI 1640 medium supplemented with
3g/mL l-glutamine (2mM), penicillin (100g/mL) and strep-
tomycin (100g/mL), and 10% fetal calf serum in ﬂat-bottomed
96-well plates at 37 ◦C in 5% CO2 (2×106 PBMC/200L/well).
Supernatants were collected after three days, and stored at −70 ◦C
until assayed.
2.8. ELISA
Antibodies (IgA, IgG and IgM) in serum and ALS samples were
measured with ELISA: microtiter plates (Polysorp, Nunc) were
coated with a preparation of LPS of Salmonella Typhi, Enteritidis,
or Typhimurium strains (10g/mL 30% methanol-PBS, all from
Sigma–Aldrich) overnight and blocked with 5% milk-PBS solution.
Next, the sampleswere serially diluted in theblocking solution, and
serum samples were added in the wells at a dilution of 1:1500, and
ALS samples at 1:150, and incubated overnight. The horseradish
peroxidase (HRP)-conjugated rabbit anti-human IgA, IgG and IgM
antibodies (Dako) were added (2h at room temperature), and the
color developed with TMB peroxidase substrate (3,3′,5,5′- tetra-
methylbenzidine and H2O2 in citric acid buffer; KPL, Gaithersburg,
USA) and stopped with 0.5M sulfuric acid. A response was deﬁned
as at least two-fold increase in the titre from the prevaccination
level in the speciﬁc antibody titres.
2.9. Statistics
Statistical analyses were carried out with JMP software version
9.0.0 (SAS Institute Inc., Cary, NC, USA). The distributions of the ASC
and HR expressions were tested with Shapiro–Wilk’s test. Since
not all distributions proved normal even after log transformations,
Bonferroni-correctedWilcoxon-signed rank testwas used for com-
parisons between the multiple groups, and Wilcoxon-signed rank
test for comparisons between two groups. Correlation analyses
were performed using the Spearman test. The results are given as
themeans,medians, and 95% conﬁdence intervals (CI) for the num-
ber of ASC, and as means ±95%CI for the HR expressions. Statistical
comparisons arepresented (a) to reveal signiﬁcant responses (com-
parisonswith anegative control,Yersinia enterocolitica; Table 1), (b)
to reveal differences to a strain against which Ty21a has in ﬁeld tri-
als been shown to provide protection (S. Typhi; Table 1, Fig. 2),
and (c) to reveal differences in the magnitude of the responses
between Salmonella strains sharing both O-9,12 or only O-12, or no
O-antigens with the Ty21a strains (various NTS strains; Table 1).
The proportions of the receptor-positive ASC were calculated as
follows: percentage of receptor-positive ASC= (100× the number
of ASC in receptor-positive cell population)/(the sum of ASC in
receptor-positive and -negative cell populations).
3. Results3.1. The ASC response in volunteers vaccinated withTy21a
Before vaccination, no ASC speciﬁc to Salmonella Typhimurium,
Agona, Stanley, Virchow, or Yersinia enterocolitica were found in
cine 30 (2012) 7238–7245 7241
t
A
a
v
n
w
S
T
P
e
S
T
o
(
I
3
T
3
w
c
f
s
3
r
t
i
n
a
p
w
s
(
b
w
a
a
o
4
r
c
p
r
s
T
s
t
S
S
r
O
t
w
s
Fig. 1. Plasmablast response to NTS strains on days 0 and 7 after Ty21a vaccination.
Numbers of circulating antigen (Salmonella Typhi, Enteritidis, Typhimurium, Agona,
Stanley, Virchow, or Hadar and Yersinia enterocolitica)-speciﬁc plasmablasts, identi-
ﬁedas antibody-secreting cells (ASC) in35volunteers vaccinatedwith theoral Ty21a
vaccine. The dots represent results of individual vaccinees and the lines the medi-
ans of the numbers of Ig(A+G+M)-plasmablasts on day 0 and 7 after vaccination.
(LOD= lower limit of detection). Statistical comparison (Wilcoxon signed rank test)
has been indicated with asterisk (*** p<0.001; ** 0.001<p<0.01; * 0.01<p<0.05).
The upper indexes +/− indicate strains with (−) no O antigen, (+) one O-antigenA. Kantele et al. / Vac
he circulation of any of the vaccinees (Fig. 1). One volunteer had 5
SC/106 PBMC reactive with Salmonella Typhi and Enteritidis, and
nother 40 ASC/106 PBMC reactive with Salmonella Hadar before
accination (Fig. 1). Seven days after vaccination, a substantial
umber of circulating Salmonella Typhi and Enteritidis-speciﬁc ASC
ere detected in all vaccinees. 32 out of 35 showed a response to
almonella Typhimurium and 31/35 to Agona, and Stanley (Fig. 1,
able 2), 6/35 and 5/35 a minor response (less than 20 ASC/106
BMC) to Virchow and Hadar, respectively, and none to Yersinia
nterocolitica. The highest cross-reactive responses were seen to
almonella Enteritidis sharing both O-antigens with Salmonella
yphi, and substantial responses were found also against strains
nly sharing one O-antigen, such as Salmonella Typhimurium
Figs. 1 and 2, Table 1). The responses were mostly dominated by
gA and IgM (data not shown).
.2. The ASC response in patients with enteric fever
All patients with enteric fever had ASC speciﬁc to Salmonella
yphi, Enteritidis, Typhimurium, Agona, and Stanley (Fig. 3).
.3. The expression of ˛4ˇ7, L-selectin and CLA on speciﬁc ASC
Almost all ASC expressed the intestinal HR, 47-integrin,
hereas the peripheral lymph node HR, L-selectin, and the
utaneous HR, CLA, were expressed less frequently (Fig. 4). No dif-
erences were seen between the HR expressions on plasmablasts
peciﬁc to the two bacterial strains.
.4. Antibodies in ALS and serum samples
The numbers of vaccinees responding with a twofold or higher
ise in antibody titres in ALS and serum samples was smaller than
hose responding in the ELISPOT assay (Table 2). With all antigens
nvestigated, there was an excellent correlation between the mag-
itudes of the IgA responses in the two plasmablast assays, ALS
nd ELISPOT (S. Typhi r=0.942 p<0.001; S. Enteritidis: r=0.9665,
< 0.01; S. Typhimurium: r=0.9837, p<0.05). Less consistency
as found between the IgM responses: some correlation was
een between ALS and ELISPOT against S. Typhi and S. Enteritidis
r=0.625, p<0.001 and r=0.3809, p<0.05, respectively), but not
etween theweak IgMresponses to S. Typhimurium.Nocorrelation
as detected between the IgG responses in the ALS and ELISPOT
ssays with any of the three strains. Responses in the plasmablast
ssays showed no correlation with serum antibody assays for any
f the three antigens.
. Discussion
The present study shows signiﬁcant cross-reactive immune
esponses against NTS strains in enteric fever and after Ty21a vac-
ination in humans. The results suggest that Ty21a vaccine could
otentially confer cross-protection against numerous NTS strains.
The immunological background accounting for the cross-
eactive immune response elicited by Ty21a against NTS is
uggested to be based on shared epitopes among the O-antigens.
y21a and Salmonella Typhi both carry O-9,12. Of the NTS strains,
ome share both of these O-antigens (e.g. Salmonella Enteri-
idis) with Ty21a, while others share only the O-12 epitope (e.g.
almonella Typhimurium, Agona, and Stanley) or none at all (e.g.
almonella Hadar and Virchow). Consistent with this, the cross-
eactive plasmablast response to Salmonella Enteritidis sharing two
-antigens was as vigorous as that to Salmonella Typhi, whereas
he responses to strains sharing only one O-antigen proved some-
hat lower. No signiﬁcant cross-reactivity was seen to strains not
haring any O-antigens. The small number of plasmablasts reactive
(O-12) or (++) two O-antigens (O-9 and O-12) in common with Ty21a.
7242 A. Kantele et al. / Vaccine 30 (2012) 7238–7245
Fig. 2. Comparisonof the typhoid-speciﬁc and cross-reactive plasmablast responses in volunteers vaccinatedwith Ty21a. Comparisonof thenumbers of circulating Salmonella
Typhi-speciﬁc ASC, with the numbers of ASC cross-reacting with Salmonella Enteritidis, Typhimurium, Agona, Stanley, Virchow, Hadar, and Yersinia enterocolitica in 35
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solunteers vaccinated with the oral Ty21a vaccine. The dots represent results of ind
n day 7 after vaccination. (LOD= lower limit of detection). The p-values of statistic
iven above the bars. The upper indexes +/− indicate strains with no O antigen (−),
ith SalmonellaVirchowandHadar in somevaccineeswaspresum-
bly due to the presence of some minor common antigens, such as
ome protein structures; using whole bacteria as antigens allows
he detection of all potentially cross-reactive antigens.
Notably, the causative agents of paratyphoid fever, Salmonella
aratyphi A and B also share the O-12 antigen with Salmonella
yphi. Consistently, we have found a cross-reactive plasmablast
esponse [29] and others have described cross-reactive cell-
ediated immune responses [30,31], and even protective efﬁcacy
f 49% by Ty21a against Paratyphi B in ﬁeld trials [32]. In fact,
e also determined the responses to S. Paratyphi A and B in the
olunteers participating in thepresent study (data not shown). Cor-
esponding to the paratyphoid strains only sharing one O-antigen
ith Ty21a, themagnitudes of the responses to paratyphoid strains
ere either lower (p<0.01 for SalmonellaParatyphiA) thanor equal
p – NS for S. Paratyphi B) to the same persons’ responses against
TS strains sharing only one O-antigen with Ty21a. The responses
able 2
ntibody responses in serum and ALS (antibodies in supernatant)-cultures. Numbers of v
nteritidis and Typhimurium. In the ELISA assays (serum and ALS), a responder was deﬁ
sotype). In the ELISPOT assay, a responder was deﬁned as having at least 3 ASC/106 PBMC
amples on days 0 and 28 after Ty21a vaccination. The number of vaccinees tested with e
Salmonella enterica serotype Responders in the assay for
Serum antibodies/ELISA 25 vaccinees ALS/EL
IgA IgG IgM IgA/IgG/IgM IgA
Typhi 7 5 12 12 (48%) 11
Enteritidis 6 6 11 11(44%) 11
Typhimurium 3 1 5 5 (20%) 7l vaccinees and the lines the medians of the numbers of Ig(A+G+M)-plasmablasts
parisons (Bonferroni corrected Wilcoxon signed rank test) between the strains are
antigen (O-12) (+) or two O antigens (O-9 and O-12) (++) in common with Ty21a.
to paratyphoid strains were signiﬁcantly lower than those against
Salmonella Enteritidis sharing twoO-antigenswith Ty21a (p<0.001
for both S. Paratyphi A and B).
The present study is the ﬁrst to explore cross-reactive
plasmablasts againstNTS strains inpatientswith typhoidorparaty-
phoid fever. Cross-reactive plasmablasts were found in all of these
patients, the proﬁle matching with the O-antigens shared between
the pathogens. It would be interesting to explore whether enteric
fever is followed by a period of protection against NTS strains bear-
ing typhoidal O-antigens.
As the cross-reactive ability of Ty21a does not cover all the NTS
strains, the clinical signiﬁcance of the potential cross-protectivity
depends on how common the strains carrying O-9 or O-12 anti-
gens are. No cross-protection can be expected against strains
without these typhoidal O-antigens. Salmonella Enteritidis, Heidel-
berg, and Typhimurium have been reported as the most common
serovars among invasive Salmonella infections in Finland, Australia,
accinees responding in serum, ALS culture and ELISPOT assays for Salmonella Typhi,
ned as an individual with at least two-fold increase in titre (in IgA, IgG and/or IgM
on day 7. Samples for ELISPOT and ALS were collected on days 0 and 7, and serum
ach assay is indicated in the Table.
ISA 13 vaccinees ASC/ELISPOT 35 vaccinees
IgG IgM IgA/IgG/IgM IgA IgG IgM IgA/IgG/IgM
6 10 11 (85%) 35 28 32 35 (100%)
4 7 11 (85%) 33 26 33 35 (100%)
3 3 7 (54%) 28 22 26 33 (94%)
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Fig. 3. Pathogen-speciﬁc and cross-reactive plasmablast responses in patients
with enteric fever. Numbers of circulating antigen (Salmonella Typhi, Enteritidis,
Typhimurium, Agona, Stanley, Virchow, or Hadar, and Yersinia enterocolitica)-
speciﬁc plasmablasts (ASC) in three patients with typhoid fever in Panel A, one
patient with relapsing typhoid fever in Panel B, and one with paratyphoid A fever
in Panel C. The dots represent the individual numbers, and the lines the medians
of Ig(A+G+M) ASC/106 PBMC on day 7–10 after the onset of infection symptoms.
(LOD= lower limit of detection). The upper indexes +/− indicate strains with no
O antigen (−), one O antigen (O-12) (+) or two O antigens (O-9 and O-12) (++) in
common with Ty21a.
Fig. 4. Homing potentials of Salmonella Typhi and Enteritidis-speciﬁc plasmablasts
after oral vaccination with Ty21a. The expression of 47, L-selectin and CLA on
Salmonella Typhi and Enteritidis -speciﬁc plasmablasts in peripheral blood of volun-
teers seven days after oral vaccination with Ty21a. The bars indicate the arithmetic
means + 95%CI of percentages of HR-positive ASC among all pathogen speciﬁc ASC
(IgA+ IgG+ IgM). The HRs and the numbers of volunteers from whom the data were
pooled are indicated under the data bars. The statistical comparisons were carried
out with Wilcoxon signed rank test. NS=not signiﬁcant.
DenmarkandCanada [33]. All these strains express the typhoidalO-
antigens. In the EU Salmonella has been reported as the main cause
of food-borne outbreaks with 165 000 conﬁrmed human cases
annually with Salmonella Enteritidis and Typhimurium represent-
ing 75% of these [11]. In the UK, in 2010, Salmonella Enteritis was
the most commonly reported serotype in humans (29%), followed
by Salmonella Typhimurium (23%), yet the numbers of Salmonella
Enteritidis have been reported to have decreased signiﬁcantly from
the previous year (-36%) [34]. On the other hand, in the USA
the incidence of Salmonella Enteritidis has been reported to be
increasing (44% rise from 1996–1999 to 2006–2009), with domes-
tic cases constituting the great majority [12]. In 2009, out of 40
828 human Salmonella cases reported to CDC, Salmonella Enteri-
tidis represented the most common strain (17%), and Salmonella
Typhimurium ranked second (15%) [10]. Antimicrobial resistance is
increasing andof the total of 1,8%nalidixic acid resistant strains, the
most common serotypes were Enteritidis (38%) and Typhimurium
(21%) [10]. On thewhole, cross-reactivitywith Ty21a is expected to
cover about half of all strains reported to CDC: approximately half
of them carried typhoidal O-antigens, one quarter both O-antigens
9 and 12, and one quarter only O-12 [10].
As the cross-reactivitymostly appears to be based on a response
against O-antigens, data on the protective efﬁcacy of O-antigen
speciﬁc antibodies are of particular interest. Numerous animal
experiments focus on this issue. Intestinal or mucosal secretory
IgA (SIgA) against SalmonellaTyphimuriumO-antigenshaveproved
protective [17–23] even in the absence of other mechanisms,
such as cell-mediated immune mechanisms [19]. Michetti and
colleagues ﬁrst showed that Sal4, a monoclonal, polymeric IgA
antibody against the Salmonella O-antigen transported into the
intestinal tractsofmicewas sufﬁcient toprotect theanimals against
an otherwise lethal oral dose of Salmonella Typhimurium [19]. Later
Sal4 was found to block the invasion of Salmonella Typhimurium
into epithelial cell monolayers, and thus prevent the earliest steps
of infection [20]. Sal4 was suggested to function by “immune
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xclusion” [20]. Forbes et al. [21] recently proposed that Sal4, by
ross-linking the O-antigen, compromises the integrity of the bac-
erial cell envelope rendering the pathogen temporarily avirulent.
mportantly, Sal4 transported intraperitoneally has not proved to
rotect the mice [19], suggesting that these antibodies are pro-
ective only at the mucosal site where they can block the ﬁrst
teps of the infection. Consistently, in a recent study, parenterally
mmunized mice did not mount detectable levels of O-antigen-
peciﬁc SIgA and none of the mice were protected against wild
ype S. Typhimurium [22]. While studies by Michetti et al. [19]
how protection against invasive disease in mice, Endt et al. have
lso shown in mice immunized with S. Typhimurium an adaptive
mmune response providing protection against a mucosal disease
n re-infection with the pathogen in an O-antigen-dependent way
22]. In humans, even if the present study provides the immunolog-
cal background for a potential protection by Ty21a against various
TS strains in humans, efﬁcacy studies are needed to separately
ssess the potential protection against local and invasive disease.
Thehomingproﬁlesof SalmonellaEnteritidis- andTyphi-speciﬁc
lasmablasts were similar, as was expected, these cells pre-
umably being the same Ty21a-speciﬁc cells, simply showing
ross-reactivity with NTS. A pronounced targeting to the intes-
ine was observed, as interpreted by the very high proportion
f cells expressing the intestinal HR 47 and lower proportion
f cells expressing L-selectin. We have previously demonstrated
hat homing proﬁles of plasmablasts depend on the site of anti-
en encounter: typhoid-speciﬁc plasmablasts exhibit an intestinal
oming proﬁle after oral administration of Ty21a, while a parente-
ally administered whole cell Ty21a vaccine induces plasmablasts
ith a systemic homing proﬁle [16]. Consistently, we have also
hown an intestinal homing proﬁle in diarrhea caused by NTS
trains [26,27]. An intestinal homing proﬁle appears particularly
eneﬁcial with respect to the intestinal transmission route of NTS
iseases, the ﬁndings in animal experiments suggesting that only
ntestinal antibodies against O-antigens prevented infections with
almonella Typhimurium [19,22].
While serum antibodies provide information on the systemic
mmune response, the plasmablast assays (ELISPOT and ALS) illus-
rate an earlier stage of the response representing thus both
ystemic andmucosal parts; in this case the lattermostly implies an
ntestinal response as seen from the homing proﬁle. Consistently,
he magnitudes of the responses in ALS and ELISPOT assays corre-
atedwith one another, but notwith the serumantibody responses.
otably, all of these assays supported cross-reactivity. Consistent
ith previous studies [15], the ELISPOT assay, representing assess-
ent at a single-cell level, proved the most sensitive approach in
he evaluation of cross-reactivity.
. Conclusions
As NTS remains a health problem of global proportions and
ntimicrobial resistance is increasing, vaccines for clinical use are
esperately needed. The present study is the ﬁrst to show that the
y21a vaccine currently available elicits a humoral cross-reactive
ut-directed, i.e. an intestinal immune response to numerous NTS
trains sharing O-antigens with Salmonella Typhi. Similar cross-
eactive responses were found in patients with enteric fever. The
TS strains include the two most commonly encountered strains
almonella Enteritidis and Typhimurium as well as many others. In
nimal experiments, intestinal antibodies against O-antigens have
roved protective. Taken together, these data provide immuno-
ogical evidence for cross-protective capacity of the Ty21a vaccine
gainst numerous NTS strains, encouraging future efﬁcacy stud-
es. Any degree of cross-protective capacity in a currently available
accine would be of tremendous value.
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